"Not only would way more people happily submit to the test but the savings to the health industry of having to avoid a boatload of unnecessary colonoscopies"
Actually, this is incorrect "unnecessary colonoscopies" is driven by the false positive rate that is a function of specificity of the assay. FIT has higher specificity than ColoSTAT (96% versus 91% hence FP rates of 4% and 9% respectively).
In other words, for every 50K people screened (assuming a CRC prevalence of 0.49%) then FIT will produce ~1,800 FP / unnecessary colonoscopies but ColoSTAT will be ~4,500 unnecessary colonoscopies.
"Not only would way more people happily submit to the test but...
Add RHY (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.002(2.94%) |
Mkt cap ! $17.40M | |||
| Open | High | Low | Value | Volume |
| 7.0¢ | 7.0¢ | 7.0¢ | $5.367K | 76.66K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 40990 | 6.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 7762 | 1 |
View Market Depth
| Last trade - 16.10pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
0.002 ( 2.94 %) |
||||
| Open | High | Low | Volume | ||
| 7.0¢ | 7.0¢ | 7.0¢ | 3917 | ||
| Last updated 14.44pm 29/05/2024 ? | |||||
| RHY (ASX) Chart |